Literature DB >> 30763935

Comparison of All-Cause and Cause-Specific Mortality of Persons with Traumatic Spinal Cord Injuries to the General Swiss Population: Results from a National Cohort Study.

Jonviea D Chamberlain1,2,3, Anne Buzzell4,5, Hans Peter Gmünder6, Kerstin Hug7, Xavier Jordan8, André Moser9, Martin Schubert10, Marcel Zwahlen11, Martin W G Brinkhof4,5.   

Abstract

BACKGROUND: Traumatic spinal cord injuries (TSCI) are a neurological condition associated with reduced well-being, increased morbidity and reductions in life expectancy. Estimates of all-cause and cause-specific mortality can aid in identifying targets for prevention and management of contributors for premature mortality.
OBJECTIVES: To compare all-cause and cause-specific rates of mortality to that of the Swiss general population; to identify differentials in risk of cause-specific mortality according to lesion characteristics.
METHODS: All-cause and cause-specific standardized mortality ratios (SMRs) were calculated using data from the Swiss Spinal Cord Injury cohort study. Cause-specific subhazard ratios were estimated within a competing risk framework using flexible parametric survival models.
RESULTS: Between 1990 and 2011, 2,492 persons sustained a TSCI, of which 379 died. Persons with TSCI had a mortality rate more than 2 times higher than that of the Swiss general population (SMR 2.32; 95% CI 2.10-2.56). Tetraplegic lesions were associated with an increased risk of mortality due to respiratory and cardiovascular diseases, infections, and accidents. Cause-specific SMRs were notably elevated for SCI-related conditions such as urinary tract infections (UTIs) and septicemia.
CONCLUSIONS: Elevated SMRs due to cardiovascular disease, UTIs and septicemia-related mortality suggest the need for innovation when managing associated secondary health conditions.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Epidemiology; Mortality; Spinal cord injury; Standardized mortality ratio

Year:  2019        PMID: 30763935     DOI: 10.1159/000496976

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

1.  Association of Secondary Health Conditions With Future Chronic Health Conditions Among Persons With Traumatic Spinal Cord Injury.

Authors:  Yue Cao; Nicole DiPiro; James S Krause
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021-01-20

2.  Attrition from specialised rehabilitation associated with an elevated mortality risk: results from a vital status tracing study in Swiss spinal cord injured patients.

Authors:  Jonviea D Chamberlain; Inge E Eriks-Hoogland; Kerstin Hug; Xavier Jordan; Martin Schubert; Martin W G Brinkhof
Journal:  BMJ Open       Date:  2020-07-09       Impact factor: 2.692

3.  All-cause and cause-specific mortality following non-traumatic spinal cord injury: evidence from a population-based cohort study in Switzerland.

Authors:  A Buzzell; J D Chamberlain; I Eriks-Hoogland; K Hug; X Jordan; M Schubert; M Zwahlen; M W G Brinkhof
Journal:  Spinal Cord       Date:  2019-10-07       Impact factor: 2.772

4.  A one-year prospective study on the occurrence of traumatic spinal cord injury and clinical complications during hospitalisation in North-East Tanzania.

Authors:  Haleluya I Moshi; Gunnevi G Sundelin; Klas G Sahlen; Ann Vm Sörlin
Journal:  Afr Health Sci       Date:  2021-06       Impact factor: 0.927

Review 5.  The Effect of miRNA-Modified Exosomes in Animal Models of Spinal Cord Injury: A meta-Analysis.

Authors:  Mengdie Hu; Zhidong Cao; Dianming Jiang
Journal:  Front Bioeng Biotechnol       Date:  2022-01-06

6.  Respiratory function and respiratory complications in spinal cord injury: protocol for a prospective, multicentre cohort study in high-income countries.

Authors:  Anja M Raab; Martin W G Brinkhof; David J Berlowitz; Karin Postma; David Gobets; Sven Hirschfeld; Maria T E Hopman; Burkhart Huber; Margret Hund-Georgiadis; Xavier Jordan; Martin Schubert; Renate Wildburger; Gabi Mueller
Journal:  BMJ Open       Date:  2020-11-05       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.